Answers are grounded in this paper and cite their sources.
The evidence for and against biochemical theories of schizophrenia has been the subject of several comprehensive reviews (1-3). In this article we will selectively discuss a number of lines of investigation which have attracted considerable recent interest. Research on the biochemistry of schizophrenia may, broadly speaking, be divided into two schools of thought: the inborn errors of metabolism model and the pharmacological model. The first derives from the strong evidence for genetic factors in the predisposition to schizophrenia (4--7) and the large number of genetic diseases in which a generalized metabolic disturbance or circulating toxic factor can now be identified. The pharmacological model, on the other hand, starts from the premise that understanding the mechanism of action of antipsychotic drugs may be expected to shed light on the pathophysiology of schizophrenia. The underlying assumption that phenothiazines and butyrophenones are not merely sedatives or tranquilizers, but act on the core symptoms of schizophrenia, is well supported by a number of clinical studies (8-12). On the whole, the search for metabolic abnormalities or circulating toxins has been disappointing. While many abnormalities have been reported, typically they have not been independently confirmed or appear to be artifacts of drug therapy, diet, stress, inactivity, or chronic infection (1). Several of the more intriguing hy potheses concerning abnormalities detectable in peripheral fluids will be discussed: the autoimmunity theory, S-protein, trans-3-methyl-2-hexenoic acid, creatine phosphokinase, histamine, and platelet monoamine oxidase.
No takes yet. Share an insight, caveat, or question.
Matthysse et al. (1975) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: